TABLE 1. Distribution across clinically relevant microbial pathogens of key biosynthetic pathways that produce metabolites targeted by human unconventional T cells.
|
Non-mevalonate pathway (Vγ9/Vδ2 T cell activation) |
Vitamin B2 synthesis (MAIT cell activation) |
|
|---|---|---|
| Gram-negative bacteria | ||
| Acinetobacter baumannii | + | + |
| Chryseobacterium gleum | − | + |
| Enterobacter cloacae | + | + |
| Escherichia coli | + | + |
| Haemophilus influenzae | + | + |
| Helicobacter pylori | + | + |
| Klebsiella pneumoniae | + | + |
| Legionella pneumophila | − | + |
| Neisseria meningitidis | + | + |
| Pseudomonas aeruginosa | + | + |
| Shigella dysenteriae | + | + |
|
| ||
| Gram-positive bacteria | ||
| Bacillus anthracis | + | + |
| Clostridium difficile | + | + |
| Corynebacterium diphtheriae | + | + |
| Enterococcus faecalis | − | − |
| Listeria monocytogenes | + | − |
| Mycobacterium tuberculosis | + | + |
| Propionibacterium acnes | + | + |
| Staphylococcus aureus | − | + |
| Streptococcus pyogenes | − | − |
|
| ||
| Other bacteria | ||
| Borrelia burgdorferi | − | − |
| Leptospira interrogans | + | + |
| Mycoplasma genitalium | − | − |
| Mycoplasma penetrans | + | − |
| Treponema pallidum | − | − |
|
| ||
| Yeasts, fungi | ||
| Aspergillus fumigatus | − | + |
| Candida albicans | − | + |
| Crytococcus neoformans | − | + |
| Saccharomyces cerevisiae | − | + |